Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders for Graphite Bio, Inc. (not Lenz Therapeutics, Inc., as indicated in the metadata), held on July 19, 2023. The filing details the voting results for the election of directors and the ratification of the independent registered accounting firm.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
Stockholders voted on two proposals at the Annual Meeting. A total of 58,102,949 shares were entitled to vote, with 44,107,052 shares present or represented by proxy.
Proposal 1: Election of Directors
Three Class II director nominees were elected to serve until the 2026 Annual Meeting:
- Abraham Bassan: 36,301,366 votes For; 2,250,503 votes Withheld.
- Matthew Porteus, M.D., Ph.D.: 35,885,476 votes For; 2,666,393 votes Withheld.
- Jo Viney, Ph.D.: 36,373,878 votes For; 2,177,991 votes Withheld.
There were 5,555,183 broker non-votes regarding this proposal.
Proposal 2: Ratification of Accounting Firm
Stockholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
- Votes For: 44,039,995
- Votes Against: 11,869
- Abstentions: 55,188
There were zero broker non-votes regarding this proposal.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on operations, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the company name discrepancy between the metadata (LENZ Therapeutics) and the filing (Graphite Bio, Inc.).
- Confirm the tenure of the newly elected directors (Class II, until 2026).
- Review the Proxy Statement filed on June 6, 2023, for detailed background on the director nominees and the rationale for the accounting firm appointment.
- Note the significant number of broker non-votes (5.5 million) on the director election proposal.